Literature DB >> 33923357

The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Nikolaos Giannakoulas1, Ioannis Ntanasis-Stathopoulos2, Evangelos Terpos2.   

Abstract

The development and effectiveness of novel therapies in multiple myeloma have been established in large clinical trials. However, multiple myeloma remains an incurable malignancy despite significant therapeutic advances. Accumulating data have elucidated our understanding of the genetic background of the malignant plasma cells along with the role of the bone marrow microenvironment. Currently, the interaction among myeloma cells and the components of the microenvironment are considered crucial in multiple myeloma pathogenesis. Adhesion molecules, cytokines and the extracellular matrix play a critical role in the interplay among genetically transformed clonal plasma cells and stromal cells, leading to the proliferation, progression and survival of myeloma cells. In this review, we provide an overview of the multifaceted role of the bone marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma.

Entities:  

Keywords:  bone disease; bone marrow; cytokines; immune cells; mesenchymal stem cells; microenvironment; multiple myeloma; osteoblasts; osteoclasts; plasma cells

Mesh：

Year:  2021        PMID： 33923357     DOI： 10.3390/ijms22094462

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  187 in total

1.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

2.  Response patterns of purified myeloma cells to hematopoietic growth factors.

Authors:  K C Anderson; R M Jones; C Morimoto; P Leavitt; B A Barut
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

3.  Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma.

Authors:  C-J Shen; Z-H Yuan; Y-X Liu; G-Y Hu
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

4.  Prognostic impact of angiopoietin-2 in multiple myeloma.

Authors:  Constantina A Pappa; Michael G Alexandrakis; Anna Boula; Aspasia Thanasia; Ioannis Konsolas; Athanasios Alegakis; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-08       Impact factor: 4.553

5.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Authors:  J M Wood; G Bold; E Buchdunger; R Cozens; S Ferrari; J Frei; F Hofmann; J Mestan; H Mett; T O'Reilly; E Persohn; J Rösel; C Schnell; D Stover; A Theuer; H Towbin; F Wenger; K Woods-Cook; A Menrad; G Siemeister; M Schirner; K H Thierauch; M R Schneider; J Drevs; G Martiny-Baron; F Totzke
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

6.  Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.

Authors:  C S Debes-Marun; G W Dewald; S Bryant; E Picken; R Santana-Dávila; N González-Paz; J M Winkler; R A Kyle; M A Gertz; T E Witzig; A Dispenzieri; M Q Lacy; S V Rajkumar; J A Lust; P R Greipp; R Fonseca
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

7.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

Review 8.  Mouse models of human myeloma.

Authors:  Constantine S Mitsiades; Kenneth C Anderson; Daniel R Carrasco
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

9.  Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.

Authors:  M Urashima; A Ogata; D Chauhan; M B Vidriales; G Teoh; Y Hoshi; R L Schlossman; J A DeCaprio; K C Anderson
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

10.  Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.

Authors:  Maria Gavriatopoulou; Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Panagiotis Malandrakis; Evangelos Eleutherakis-Papaiakovou; Athanasios Papatheodorou; Nikolaos Kanellias; Magdalini Migkou; Despina Fotiou; Ioanna Dialoupi; Maria Roussou; Nikoletta-Aikaterini Kokkali; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2020-03-02       Impact factor: 11.037
View more
  9 in total

1.  CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.

Authors:  Noa Gross Even-Zohar; Marjorie Pick; Liron Hofstetter; Adir Shaulov; Boaz Nachmias; Eyal Lebel; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-05-20       Impact factor: 4.964

2.  "Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan".

Authors:  Adeeba Zaki; Salman Muhammad Soomar; Danish Hasan Khan; Hasan Shaharyar Sheikh; Raheel Iftikhar; Ayaz Mir; Zeba Aziz; Khadija Bano; Hafsa Naseer; Qamar Un-Nisa Chaudhry; Syed Waqas Imam Bokhari; Munira Shabbir-Moosajee
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.752

Review 3.  Metabolic Disorders in Multiple Myeloma.

Authors:  Maria Gavriatopoulou; Stavroula A Paschou; Ioannis Ntanasis-Stathopoulos; Meletios A Dimopoulos
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

4.  Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2.

Authors:  Jianmei Gu; Maoye Wang; Xinfeng Wang; Jiao Li; Haiyan Liu; Zenghua Lin; Xi Yang; Xu Zhang; Hong Liu
Journal:  Front Cell Dev Biol       Date:  2022-03-01

Review 5.  Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.

Authors:  Eyal Lebel; Boaz Nachmias; Marjorie Pick; Noa Gross Even-Zohar; Moshe E Gatt
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

6.  GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.

Authors:  Andrea Kosta; Abdelilah Mekhloufi; Lorenzo Lucantonio; Alessandra Zingoni; Alessandra Soriani; Marco Cippitelli; Angela Gismondi; Francesca Fazio; Maria Teresa Petrucci; Angela Santoni; Helena Stabile; Cinzia Fionda
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

Review 7.  The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Zhigang Yi; Tao Ma; Jia Liu; Wenting Tie; Yanhong Li; Jun Bai; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

8.  CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.

Authors:  Cesarina Giallongo; Ilaria Dulcamare; Francesco Di Raimondo; Giuseppe A Palumbo; Daniele Tibullo; Vittorio Del Fabro; Nunzio Vicario; Nunziatina Parrinello; Alessandra Romano; Grazia Scandura; Giacomo Lazzarino; Concetta Conticello; Giovanni Li Volti; Angela Maria Amorini; Giuseppe Musumeci; Michelino Di Rosa; Francesca Polito; Rosaria Oteri; M'hammed Aguennouz; Rosalba Parenti
Journal:  Oncogenesis       Date:  2022-01-21       Impact factor: 7.485

9.  The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.

Authors:  Reiko Isa; Mano Horinaka; Taku Tsukamoto; Kentaro Mizuhara; Yuto Fujibayashi; Yoko Taminishi-Katsuragawa; Haruya Okamoto; Shusuke Yasuda; Yuka Kawaji-Kanayama; Yayoi Matsumura-Kimoto; Shinsuke Mizutani; Yuji Shimura; Masafumi Taniwaki; Toshiyuki Sakai; Junya Kuroda
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.